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Abstract Sphingolipids such as ceramide and sphingosine are
putative intracellular signal mediators in cell di¡erentiation,
growth inhibition and apoptosis. Previously, we reported that
C2-ceramide induced c-jun expression in apoptosis of human
leukemia HL-60 cells. Here we report that sphingosine also
induced c-jun expression in apoptosis of HL-60 cells. Sphingo-
sine-induced c-jun expression was stimulated by H-89, a protein
kinase A inhibitor, whereas C2-ceramide-induced c-jun expres-
sion was inhibited by protein kinase C inhibitors. Furthermore,
H-89 potentiated sphingosine-induced but not C2-ceramide-in-
duced growth inhibition. These results suggest that sphingosine
and C2-ceramide might induce c-jun expression and apoptosis in
distinct signaling pathways. * 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Sphingolipids such as ceramide and sphingosine have
emerged as novel intracellular signal mediators [1]. Various
studies have shown that ceramide is involved in cell death
(apoptosis) and growth inhibition (for reviews see [2]). In-
crease of ceramide and/or activation of (acidic and neutral)
sphingomyelinases have been detected in apoptosis induced by
many stimuli, including tumor necrosis factor-K, anti-Fas
antibody, anti-cancer drugs, and irradiation [3^6]. We previ-
ously showed that C2-ceramide induced c-jun expression at
the transcriptional level and increased DNA binding activity
of AP-1 [7]. We also reported that antisense oligonucleotides
of c-jun suppressed C2-ceramide-induced apoptosis [7]. An-
other group showed that overexpression of a dominant neg-
ative form of c-Jun inhibited ceramide-induced apoptosis [8].
These results suggested that activation of AP-1 might be re-
quired for ceramide-mediated apoptotic signaling pathway.
Sphingosine, an N-deacylated form of ceramide, is a potent
inhibitor of protein kinase C (PKC) [9]. Sphingosine also in-
duces apoptosis and growth inhibition in various cell types
[10,11]. However, the mechanisms by which sphingosine in-
duces apoptosis remain unclear.
Here we show that sphingosine induces c-jun expression in
HL-60 cells. Furthermore, we show that H-89, a protein ki-
nase A (PKA) inhibitor, potentiates sphingosine-induced c-jun
expression and growth inhibition, whereas staurosporine, a
PKC inhibitor, suppresses C2-ceramide-induced c-jun expres-
sion and apoptosis. These results suggest the requirement of c-
jun expression for sphingosine-induced apoptosis and growth
inhibition, and also suggest di¡erent mechanisms between
sphingosine- and C2-ceramide-induced c-jun expression.
2. Materials and methods
2.1. Materials
Sphingosine was purchased from Sigma. D-Erythro-C2-ceramide
and C18-ceramide were purchased from Matreya (USA). H-89 and
H-7 were purchased from Seikagaku (Japan). Diacylglycerol kinase
was a gift from Dr. Yusuf A. Hannun (Medical University of South
Carolina, USA). Other chemicals were purchased from Sigma (USA).
Sphingosine and C2-ceramide was dissolved in ethanol. C18-ceramide
was dissolved in ethanol/dodecane (98:2).
2.2. Cell culture
Human myelogenous leukemia HL-60 cells were maintained in
RPMI 1640 medium containing 10% heat-inactivated fetal bovine
serum at 37‡C in a 5% CO2 incubator. HL-60 cells in exponentially
growing phase were washed once with RPMI 1640 medium containing
5 Wg/ml transferrin and 5 Wg/ml insulin instead of serum, resuspended
in the serum-free medium overnight at a concentration of 5U105 cells/
ml, and then used for experiments.
2.3. Cell counting
Viable cell number was determined under microscope by trypan
blue dye exclusion test.
2.4. Apoptosis
Apoptotic cells were determined under microscope by typical mor-
phological changes such as nuclear fragmentation and formation of
apoptotic body. At least 200 cells were examined in each experiment.
2.5. Northern blot analysis
Total RNA was extracted by using ISOGEN (Nippon Gene, Japan)
according to the manufacturer’s protocol. Northern blotting was per-
formed as described previously [7]. Brie£y, human c-jun oligonucleo-
tide probe (Oncogene Science, USA) was 5P-end labeled by using a
Kination kit (Toyobo, Japan), and puri¢ed through Sephadex G-25
spun column twice. Hybridizations were performed at 42‡C for 24 h,
and then the membranes were washed in 2Usaline sodium citrate
(0.15 M NaCl, 15 mM sodium citrate)/0.1% sodium dodecyl sulfate
at room temperature for 30 min and at 50‡C for 20 min. The mem-
branes were exposed to X-ray ¢lms with intensifying screens at 380‡C
for 2 days. Equal loading of RNA on each lane was con¢rmed by
methylene blue staining of the membrane.
2.6. Ceramide measurement
The levels of ceramide were determined by using diacylglycerol ki-
nase as described [12].
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3. Results
3.1. Induction of c-jun mRNA expression by sphingosine
We reported that C2-ceramide induced c-jun expression and
apoptosis in HL-60 cells [7]. As previously reported [10],
sphingosine (5 WM) induced apoptosis in HL-60 cells (data
not shown). Therefore, we examined whether the expression
of c-jun mRNA was induced by sphingosine. As shown in Fig.
1A, Northern blot analysis demonstrated that the levels of c-
jun mRNA (2.7 and 3.2 kb) were increased by treatment with
sphingosine. The expression of c-jun mRNA increased at 30
min, peaked at 1 h, and then gradually decreased. The time
course of c-jun induction by sphingosine was similar to that
by C2-ceramide. Fig. 1B showed that c-jun mRNA was in-
duced by sphingosine in a dose-dependent manner up to 10
WM. It seemed that C2-ceramide induced c-jun expression
more strongly (approximately three- to ¢ve-fold) than sphin-
gosine at the same concentration (5 WM).
Recently, it was reported that natural long-chain ceramide
could induce apoptosis by usage of dodecane [13]. Therefore,
we examined the e¡ect of natural ceramide with dodecane on
c-jun induction. Increase of c-jun expression was observed 4 h
after treatment with natural ceramide (Fig. 1C). The level of
c-jun mRNA was further increased at 8 h. Because the time-
course of c-jun induction by natural ceramide was much slow-
er than that by sphingosine or C2-ceramide, natural ceramide
was not used in the experiments described below.
3.2. No e¡ect of fumonisin B1 on sphingosine-induced c-jun
expression and apoptosis
Because sphingosine could be converted to ceramide by N-
acylation and ceramide could induce c-jun expression, we used
fumonisin B1, an inhibitor of ceramide synthase, to investigate
whether sphingosine itself induced c-jun expression. As shown
Fig. 1. Sphingosine-induced c-jun expression. A: Time-course of
sphingosine-induced c-jun expression. HL-60 cells were treated with
either 0.1% ethanol vehicle (C) or 10 WM sphingosine (Sp) for the
indicated times. B: Dose dependence of sphingosine-induced c-jun
expression. HL-60 cells were treated with the indicated concentra-
tions of sphingosine for 1 h. C2, treated with 5 WM C2-ceramide
for 1 h. C: Natural ceramide-induced c-jun expression. HL-60 cells
were treated with either 0.1% ethanol/dodecane (98:2) vehicle or 0.5
or 1 WM C18-ceramide dissolved in ethanol/dodecane (98:2) for the
indicated times. Northern blot experiments were performed as de-
scribed in Section 2. The results are representative of three di¡erent
experiments. Equal loading of RNA on each lane was con¢rmed by
methylene blue staining of the membrane.
Fig. 2. No e¡ect of fumonisin B1 on sphingosine-induced c-jun ex-
pression and apoptosis. A: HL-60 cells were pretreated with or
without 100 WM fumonisin B1 (Fu) for 30 min and then treated
with 0.1% ethanol vehicle or 10 WM sphingosine (Sp) for 1 h. The
levels of ceramide were determined as described in Section 2. The
results are representative of two di¡erent experiments. The data
show means plus S.D. of duplicate counts. B: The levels of c-jun
mRNA were determined as described in Section 2. The results are
representative of two di¡erent experiments. C: HL-60 cells were pre-
treated with or without 100 WM fumonisin B1 (Fu) for 30 min and
then treated with 0.1% ethanol vehicle or 10 WM sphingosine (Sp)
for 4 h. Apoptosis was assessed under microscope by typical mor-
phological changes such as nuclear fragmentation and formation of
apoptotic bodies. At least 200 cells were examined in each experi-
ment. The data show means plus S.D. of three di¡erent experi-
ments.
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in Fig. 2A, treatment with sphingosine greatly increased the
level of ceramide, presumably by N-acylation of sphingosine
in cells. When cells were treated with both sphingosine and
fumonisin B1, generation of ceramide from sphingosine was
inhibited by more than 50%. However, fumonisin B1 did not
signi¢cantly inhibit sphingosine-induced c-jun expression (Fig.
2B). Furthermore, sphingosine-induced apoptosis was not
suppressed by co-treatment with fumonisin B1 (Fig. 2C).
These results suggest that sphingosine itself could induce c-
jun expression and apoptosis without conversion to ceramide.
3.3. E¡ects of kinase inhibitors on c-jun induction by
sphingosine and C2-ceramide
Because it has been reported that activation of PKA and
PKC induced the expression of c-jun mRNA, we examined
whether PKA and PKC were involved in c-jun induction by
sphingosine. As shown in Fig. 3, sphingosine-induced c-jun
expression was stimulated by H-89 (a PKA inhibitor). The
level of c-jun mRNA treated with sphingosine and H-89
was approximately three-fold compared to that with sphingo-
sine alone. H-7 or staurosporine (PKC inhibitors) did not
signi¢cantly a¡ect sphingosine-induced c-jun expression.
These results suggest that inhibition of PKA might be in-
volved in c-jun induction by sphingosine.
To investigate whether C2-ceramide induced c-jun expres-
sion by a similar mechanism with sphingosine, we examined
the e¡ects of PKA and PKC inhibitors on c-jun induction by
C2-ceramide. As shown in Fig. 3, H-89 did not a¡ect C2-
ceramide-induced c-jun expression, whereas H-7 and stauro-
sporine strongly inhibit c-jun induction by C2-ceramide.
These results suggest that activation of PKC might be in-
volved in c-jun induction by C2-ceramide, demonstrating the
di¡erence between the mechanisms by which sphingosine and
C2-ceramide induced c-jun expression.
3.4. Potentiation of sphingosine-induced growth inhibition by
H-89
We previously reported that C2-ceramide induced apoptosis
and inhibited cell growth through induction of c-jun and ac-
tivation of AP-1. Because H-89 stimulated sphingosine-in-
duced c-jun expression, we examined whether H-89 potenti-
ated sphingosine-induced growth inhibition. As shown in Fig.
4, treatment with sphingosine and H-89 signi¢cantly inhibited
cell growth compared to treatment with sphingosine alone.
Furthermore, H-89 did not a¡ect C2-ceramide-induced
growth inhibition. As we previously reported [14], staurospo-
rine inhibited C2-ceramide-induced apoptosis and growth in-
hibition, whereas sphingosine-induced growth inhibition was
not a¡ected by staurosporine (data not shown). These results
further suggest that c-jun induction might be required for C2-
ceramide- and sphingosine-induced apoptosis and growth in-
hibition.
4. Discussion
It has been proposed that ceramide may function as a bio-
stat regulating cell growth and apoptosis. Sphingosine, an N-
deacylated form of ceramide, is also a potent inducer of ap-
optosis and growth inhibition. However, the mechanisms by
which ceramide and sphingosine exert these e¡ects remain to
be elucidated. Here we demonstrated that (i) sphingosine (as
well as ceramide) induced c-jun expression, (ii) sphingosine-
induced c-jun expression was stimulated by H-89, a PKA in-
hibitor, whereas C2-ceramide-induced c-jun expression was
not a¡ected by H-89, (iii) sphingosine-induced c-jun expres-
sion was only slightly a¡ected by PKC inhibitors, whereas C2-
ceramide-induced c-jun expression was strongly inhibited by
PKC inhibitors. These results suggested that inhibition of
PKA might be involved in c-jun induction by sphingosine,
whereas activation of PKC might be involved in c-jun induc-
tion by C2-ceramide. It seemed quite surprising that sphingo-
sine and C2-ceramide induced c-jun expression by distinct
mechanisms, considering the similarities in structure between
sphingosine and C2-ceramide.
Furthermore we showed that H-89, which stimulated sphin-
gosine-induced c-jun expression, potentiated sphingosine-in-
duced growth inhibition. Previously, we demonstrated the re-
quirement of c-jun/AP-1 activation in C2-ceramide-induced
apoptosis and growth inhibition. Consistent with this, stauro-
sporine, which inhibited C2-ceramide-induced c-jun expres-
sion, suppressed C2-ceramide-induced apoptosis. These results
suggested that c-jun induction might be required in sphingo-
sine-induced apoptosis and growth inhibition.
Further studies will be needed to elucidate the signaling
Fig. 3. E¡ects of PKA or PKC inhibitors on sphingosine- or C2-
ceramide-induced c-jun expression. HL-60 cells were treated with ei-
ther 10 WM sphingosine (Sp) or C2-ceramide (C2) alone or plus
1 WM H-89 (H89), 10 WM H-7 (H7), or 10 WM staurosporine (St)
for 1 h. C: treated with 0.1% ethanol vehicle. Northern blot experi-
ments were performed as described in Section 2. The results are rep-
resentative of three di¡erent experiments. Equal loading of RNA on
each lane was con¢rmed by methylene blue staining of the mem-
brane.
Fig. 4. E¡ect of H-89 on sphingosine- or C2-ceramide-induced
growth inhibition. HL-60 cells at a concentration of 2U105 cells/ml
were treated with either 3 or 5 WM sphingosine or 2 WM C2-ceram-
ide alone or plus 0.5 WM H-89 for 24 h. Viable cell numbers were
counted under microscope by trypan blue dye exclusion test. C:
treated with 0.1% ethanol vehicle. The results are representative of
three di¡erent experiments. The data show means plus S.D. of trip-
licate counts.
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pathways in c-jun expression induced by sphingosine and cer-
amide.
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